HOME > TOP STORIES

TOP STORIES

REGULATORY MHLW to Launch New Project to Strengthen Generic Drug Use in Around 10 “Priority Prefectures” Aiming at 80% Volume Share Target

January 25, 2018
BUSINESS Biogen Japan to Kick Off PIII Study for Stroke Drug by Year-End

January 24, 2018
REGULATORY Shionogi’s Sakigake-Designated Flu Med Up for MHLW Panel Review on Feb. 2, Early Listing Possible?

January 23, 2018
REGULATORY MHLW OKs Dupixent, Tecentriq, Lynparza, and More

January 22, 2018
BUSINESS Industry Expresses Disappointment about “Expansion” of Essential Drugs; Some Looking to Real Expansion in FY2020

January 19, 2018
BUSINESS Another Drug Lag “Will” Arise, Says Mitsubishi Tanabe President after JPMA Chief’s Denial

January 19, 2018
REGULATORY Huge Seller Price Slash to Hit Nexium/Takecab; Rituxan, 8 Other Brands to Face Market Expansion Re-Pricing

January 18, 2018
REGULATORY Chuikyo OKs Special Re-Pricing for FY2018 Drug Price Revision, Here’s the List of Products

January 17, 2018
REGULATORY MHLW Health Policy Chief Wants Pricing Reform to Prod Drug Makers’ Overseas Expansions

January 17, 2018
BUSINESS Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed

January 16, 2018
ORGANIZATION Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief

January 15, 2018
REGULATORY Streamlining Regulations of Pharmaceutical Affairs to Be “a Top Priority” in 2018: MHLW Pharma Bureau Chief

January 12, 2018
BUSINESS Will Symbicort and Adoair Face Generic Entries This Year? Trade Group Has Seen High Hurdle for Inhaler Drugs

January 11, 2018
REGULATORY Balancing Innovation and Universal Coverage Was Key in Drug Pricing Reform: Health Minister

January 10, 2018
REGULATORY PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive

January 9, 2018
BUSINESS Will Pricing Reform Spur Divestment of Off-Patent Brands in Japan? Next 3 Months Hold Key for Future Directions

January 1, 2018
BUSINESS Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec

December 27, 2017
BUSINESS MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?

December 26, 2017
REGULATORY “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market

December 25, 2017
ORGANIZATION JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief

December 22, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…